#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15940	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2534	759.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	2030	2030	T	980	T,G	977,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15940	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2534	759.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1764	1764	C	1017	C,A	1016,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15940	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2534	759.7	0	HET	.	.	.	A69G	.	69	69	A	649	649	A	1019	A,G	813,206	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15940	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2534	759.7	0	HET	.	.	.	C262T,A	.	262	262	C	842	842	C	974	C,T,A	757,213,4	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26966	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4017	836.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1873	1873	A	1115	A,G	1113,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26966	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4017	836.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2507	2507	C	922	C,A	921,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26966	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4017	836.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2581	2581	A	834	A	834	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26966	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4017	836.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3133	3133	C	968	C,T,A	966,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2474	folP	852	852	99.88	folP.l15.c4.ctg.1	2119	145.5	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1103	1105	AAA	252;254;256	A;A,C;A,C	252;253,1;255,1	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2474	folP	852	852	99.88	folP.l15.c4.ctg.1	2119	145.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1334	1336	AGC	218;216;217	A;G;C	218;216;217	folP.WHO_W_01420c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5664	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3886	181.8	1	SNP	p	S91F	0	.	.	271	273	TCC	859	861	TCC	208;212;212	T,G;C,A;C	207,1;209,3;212	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5664	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3886	181.8	1	SNP	p	D95G	0	.	.	283	285	GAC	871	873	GAC	222;224;225	G,T;A,C;C	221,1;222,2;225	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5664	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3886	181.8	1	SNP	p	D95N	0	.	.	283	285	GAC	871	873	GAC	222;224;225	G,T;A,C;C	221,1;222,2;225	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	2274	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1747	162.2	1	SNP	p	G45D	0	.	.	133	135	GGC	697	699	GGC	264;264;265	G,T;G;C	263,1;264;265	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1264	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1432	109.8	0	.	n	.	0	A197.	DEL	197	197	A	856	856	A	257	A	257	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5664	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3329	211.6	1	SNP	p	D86N	0	.	.	256	258	GAC	812	814	GAC	232;228;229	G;A;C	232;228;229	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5664	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3329	211.6	1	SNP	p	S87W	0	.	.	259	261	AGT	815	817	AGT	228;232;231	A;G;T	228;232;231	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5664	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3329	211.6	1	SNP	p	S87I	0	.	.	259	261	AGT	815	817	AGT	228;232;231	A;G;T	228;232;231	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5664	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3329	211.6	1	SNP	p	S87R	0	.	.	259	261	AGT	815	817	AGT	228;232;231	A;G;T	228;232;231	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5664	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3329	211.6	1	SNP	p	S88P	0	.	.	262	264	TCC	818	820	TCC	233;233;235	T,A;C;C	232,1;233;235	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4732	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3100	190.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1759	1761	GGC	293;291;288	G,T;G;C,A	292,1;291;287,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1501	1503	GCA	272;272;271	G,T;C;A	271,1;272;271	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1504	1506	ATC	271;267;270	A,C,G;T;C,A	268,2,1;267;269,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1516	1518	GTG	269;268;272	G,T;T,G;G,C	268,1;267,1;271,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1516	1518	GTG	269;268;272	G,T;T,G;G,C	268,1;267,1;271,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2020	2022	ACC	235;235;235	A;C;C	235;235;235	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2074	2076	GCG	228;230;232	G;C;G,C	228;230;231,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2074	2076	GCG	228;230;232	G;C;G,C	228;230;231,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2197	2199	GGC	242;243;246	G;G;C,T,G	242;243;243,2,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2206	2208	GGC	238;239;237	G;G,T;C	238;238,1;237	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4318	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2882	187.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2224	2226	CTG	237;238;239	C;T;G	237;238;239	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5914	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3546	208.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1861	1863	CCG	255;253;246	C,T,A;C;G	252,2,1;253;246	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2692	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2185	153.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	730	730	C	200	C	200	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	26;26;27	T;T;A	26;26;27	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	57;57;57	C;A;T	57;57;57	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	57;57;57	A;G;T	57;57;57	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	57;57;57	T;A;C	57;57;57	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	5;5;5	G;A;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	5;6;6	A;T;C	5;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	7;7;7	T;C;G	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	7;7;8	G;C;C	7;7;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	8;8;8	A;G;C	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	8;8;8	G,T;C;C	7,1;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	312	29.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	9;9;9	G;T;T	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	100	94.0	porB1a.l15.c17.ctg.4	182	49.4	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	52;50;45	A;C;G	52;50;45	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	288	porB1a	984	100	94.0	porB1a.l15.c17.ctg.4	182	49.4	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	14;14;11	C;A;A	14;14;11	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3060	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1857	203.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	549	551	GAA	259;259;258	G;A,T,C;A	259;257,1,1;258	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3060	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1857	203.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	837	839	GAT	234;230;229	G,A;A;T,G	233,1;230;228,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3060	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1857	203.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	960	962	TCA	276;274;275	T;C,A;A,G	276;273,1;274,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3060	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1857	203.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1089	1091	GTC	266;267;269	G;T;C	266;267;269	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3060	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1857	203.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1419	1421	GCA	287;287;290	G,T;C,A;A	286,1;286,1;290	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3060	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1857	203.8	1	SNP	p	G120K	1	.	.	358	360	AAG	795	797	AAG	230;230;230	A;A,T;G,A	229;228,1;229,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3060	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1857	203.8	1	SNP	p	D121N	0	.	.	361	363	GAC	798	800	GAC	229;234;236	G;A;C	228;233;235	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3060	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1857	203.8	1	SNP	p	A121D	1	.	.	361	363	GAC	798	800	GAC	229;234;236	G;A;C	228;233;235	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10632	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5357	247.6	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2241	2243	AAT	273;269;269	A;A;T,G	273;269;268,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1562	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1393	139.2	1	SNP	p	V57M	1	.	.	169	171	ATG	700	702	ATG	270;268;268	A;T;G,T	270;268;267,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
